Aditya Bardia, MD, MPH, director of translational research integration, UCLA, explains how metastatic estrogen receptor-positive breast cancers can develop ESR1 mutations. Donald McDonnell, PhD, research scientist, Duke University, Durham, North Carolina, discusses how these mutations are different from inherited gene mutations, such as BRCA1/2.
More Videos in Metastatic Breast Cancer Content Hub
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
Angela Belcher, PhD; Sangeeta Bhatia, MD, PhD; and Paula Hammond, PhD, from the Koch Institute at MIT, Cambridge, MA, present multi-dimensional approaches to early detection in ovarian cancer.…
Sramila Aithal, MD, medical oncologist, Cancer Treatment Centers of America, discusses optimization of therapy for patients with HER2-positive metastatic breast cancer. Dr Authal shares her experience with toxicity…
Approximately 30% of women with early-stage breast cancer will face metastatic disease, and 6% are diagnosed with metastatic breast cancer initially. Living with metastatic breast cancer can elicit…
Tufia C. Haddad, MD, an oncologist at Mayo Clinic, Rochester, Minnesota, discusses what to expect before, during, and after initial treatment for metastatic breast cancer. Dr Haddad emphasizes…
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Barbara Pistilli, MD, chair of the breast cancer unit, Gustave Roussy, Villejuif, France, provides a case-based discussion of therapeutic options for a patient with pretreated HR+/HER2- (IHC 0)…
